1 completed, 1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow C. Babis Andreadis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells - Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 1 | Recruiting | C. Babis Andreadis | 36 | 2020-09-11 | 2026-06-22 |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML Ficlatuzumab, Cytarabine - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Terminated | C. Babis Andreadis | 17 | 2015-05-01 | 2020-03-24 |
| Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ofatumumab, Etoposide, Cytarabine - Diffuse Large Cell Lymphoma Relapsed/Refractory | Phase 2 | Completed | C. Babis Andreadis | 19 | 2012-05-25 | 2022-06-29 |
Burkitt Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Recurrence (1)
Cytarabine (2) · Automobiles (1) · Cyclophosphamide (1) · Etoposide (1) · Immunotherapy, Adoptive (1) · Therapeutics (1) · ficlatuzumab (1) · fludarabine (1) · fludarabine phosphate (1) · ofatumumab (1)
United States (3)
Carrie Ho, MD (1) · Charalambos Andreadis, MD (1) · Charalambos Andreadis, MD, MSCE (1)